Prevymis (letermovir) - Merck (MSD)
Impact of CMV-specific immune reconstitution at the end of letermovir prophylaxis on the development of late cytomegalovirus infection in haematopoietic stem cell transplant recipients (INMUNOEND): a protocol for a prospective, observational, multicentre study. (PubMed, BMJ Open) - Oct 16, 2025 - P | "The results of this study will be published in peer-reviewed journals and disseminated at national and international conferences. NCT06814301." 
Clinical protocol • Journal • Observational data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/41093321
 
Aurora Páez-Vega; Carmen Martín; Clara Aparicio; Concepcion Herrera; Elisa Ruiz-Arabi; Estefanía García; Francisco Manuel Martín Domínguez; Isabel Machuca; Juan José Castón; Juan Manuel Cerezo-Martín; Julián Torre-Cisneros; Lorena Pozo López; María Ángeles Cuesta-Casas; María Aránzazu Bermúdez-Rodríguez; Pedro Antonio González-Sierra; Raquel Saldaña-Moreno
 
Oct 16, 2025
 
Prev Next